Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Its prospectus says that the IPO will fund phase 1 and phase ... in the footsteps of obesity drug developer Metsera and genetic medicines developer Maze Therapeutics, which filed to list on ...

Metsera’s (NASDAQ:MTSR – Get Free Report) quiet period is set to expire on Wednesday, March 12th. Metsera had issued 15,277,778 shares in its initial public offering on January 31st. The total size of ...

We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Maze Therapeutics’ (NASDAQ:MAZE – Get Free Report) quiet period will expire on Wednesday, March 12th. Maze Therapeutics had issued 8,750,000 shares in its initial public offering on January 31st. The ...

The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

On February 3rd, three insiders acquired a total of $94.22 million in Metsera shares at $18 per share during the company’s ...

Explore Metsera stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for MTSR. Why Did MTSR Stock Surge 15% On The Worst Trading Day Of 2025? Here's What Has ...

Just kidding, all you need to do is click your mouse, and your avatar will do all the walking in the Maze Simulator. You can never be entirely sure you’ve typed in a code correctly if you’re ...